CRISPR milestone: FDA approves first diagnostic test

May 7th 2020 will be remembered as a good day for CRISPR. Yesterday the first CRISPR/Cas-based test received Emergency Use Authorization from the U.S. Food and Drug Administration. The Sherlock SARS-CoV2 kit works by programming a CRISPR enzyme to detect the coronavirus genetic signature, providing results in about one hour. Quickly and cheaply indeed, as the materials for one test cost about $6.

Continue reading

When CARMEN met the coronavirus

Say hello to CARMEN: a massively multiplexed, Cas13-based technology for nucleic acid detection, out yesterday in Nature. Its name stands for Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids, and it allows us to test many amplified samples for the presence of many viral sequences by using miniaturized detection reactions that self-organize in a microwell array. Sars-Cov2 included.

Continue reading

CRISPR application to infectious diseases

CRISPR holds promise for the treatment of cancer and inherited disorders, as you know, but what about infectious diseases? It can do many useful things indeed, according to this review by Jeffrey Strich and Daniel Chertow, published in the Journal of Clinical Microbiology.

Continue reading

Toward a CRISPR-based diagnostics for COVID-19

Do you remember Sherlock? The CRISPR-based platform was heralded in Science as a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. The good news is that Feng Zhang and colleagues are sharing a research protocol, applicable to purified RNA, that may inform the development of a Sherlock test for COVID-19. For more information, visit the McGovern Institute website.

The CRISPR diagnostics era is here

ZikaTest_Paper-based-results-002-1024x576Elementary dear Watson, we should have expected that. The CRISPR wave is hitting diagnostics, with a new high sensitivity detection platform named after Arthur Conan Doyle’s popular detective. The acronym SHERLOCK stands for “Specific High Sensitivity Enzymatic Reporter UnLOCKing”. While the technique is used in thousands of labs to turn genes on and off, CRISPR embarks also on epidemiology and learns how to identify nucleic acids from viral and bacterial pathogens to diagnose infections. The paper published in Science by James Collins, Feng Zhang and colleagues heralds a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. Continue reading